Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT ...

By Vijay Kumar Malesu In an interim analysis of an ongoing global trial, semaglutide resolved steatohepatitis in 63% of ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

A recent analysis of data from the SELECT trial of semaglutide in overweight or obese patients found that the cardiovascular benefits of the drug seemed to accrue regardless of how much weight ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

The STEP-HFpEF data have emerged shortly after semaglutide became the first drug in the category to reduce cardiovascular outcomes in the phase 3 SELECT trial, revealing that it reduced the risk ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...